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<<abs>> 
Objective. To compare practice patterns and prescribing differences for juvenile 
idiopathic arthritis (JIA) between adult rheumatologists (ARs) and pediatric 
rheumatologists (PRs), the perceived educational needs, and factors that enhance or 
impede co-management. 
Methods. Two parallel, cross-sectional surveys focusing on JIA were administered in 
2009 to a random sample of 193 PRs and 500 ARs using the American College of 
Rheumatology membership file. Bivariate analysis was conducted for common items. Au
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Results. The response rate was 62.1% for ARs (n = 306) and 72.3% for PRs (n = 
138). Only 23% of responding ARs (n = 69) reported caring for children with JIA. Of 
these, 94% strongly agreed/agreed feeling comfortable diagnosing JIA; however, only 
76% felt comfortable treating JIA. Clinical vignettes highlighted several prescribing 
differences. Forty-eight percent of ARs and 31% of PRs felt medications to treat JIA did 
not have clear dosing guidelines. Though PRs initiated disease-modifying antirheumatic 
drugs and biologic agents earlier, treatments were similar after 3 months. To enhance co-
management, 74% of pediatric respondents endorsed shared medical records. 
Conclusion. Nearly one-quarter of surveyed ARs care for children with JIA, with most 
limiting their practice to older children. There was more discomfort in treating JIA than 
diagnosing it, and there were significant prescribing differences. Both provider types 
identified the need for better dosing and treatment resources. Updated management 
guidelines along with exposure to pediatric rheumatology in fellowship could reduce 
treatment differences and enhance the care of children with JIA. Shared medical records 
and improvement in reimbursement may optimize co-management. 
<</abs>> 
 
<<hd1>>INTRODUCTION  
Rheumatologic diseases of childhood affect 300,000 children in the US and are 
associated with significant morbidity (1,2). For providers, pediatric rheumatology 
patients present unique challenges that are related to the rarity of these conditions and 
their variable presentation and disease course. Due to the national shortage of pediatric 
rheumatologists (PRs) (2), an estimated half of US children with rheumatologic disease 
are being cared for by adult rheumatologists (ARs) (2,3). Treatments for pediatric 
rheumatologic diseases have evolved substantially over the past few decades, resulting in 
decreased morbidity and mortality and also higher demands on providers for monitoring 
newer, higher-risk medications (4–7). However, many ARs (8) and primary care 
providers (9) who treat children report being uncomfortable caring for childhood 
rheumatologic disease patients and do not perceive themselves as up to date on the 
current pediatric treatments. It is not known how variations in treatment selection and 
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dosing relate to subspecialty (pediatric versus adult rheumatology), fellowship training, 
and information resources.  
 
SIGNIFICANCE & INNOVATIONS • To our knowledge, these results provide the first detailed national description of 
treatment choices among adult rheumatologists who report caring for children with 
juvenile idiopathic arthritis. • The clinical vignettes used in this survey study highlight important differences in 
treatment patterns, both for initial and refractory cases, between pediatric and adult 
rheumatologists and demonstrate significant prescribing differences between adult 
rheumatologists with and without training from a pediatric rheumatologist. • While the lack of pediatric rheumatologists is cited as a common reason for adult 
providers caring for children, this study suggests factors other than just distance to a 
pediatric provider may be impacting access to care. 
 
To explore these issues, we conducted a national survey of ARs and PRs, with the 
following specific aims: 1) compare AR and PR current practice patterns for children 
with rheumatologic disease, including choice of medications, 2) compare the current and 
preferred resources used by ARs and PRs in caring for children with rheumatologic 
conditions, and 3) describe factors that enhance or impede effective co-management of 
pediatric rheumatology patients between ARs and PRs.  
 
<<hd1>>MATERIALS AND METHODS 
 
This cross-sectional, self-administered mail survey was conducted with a national sample 
of ARs and PRs in the US and was approved by the University of Michigan Institutional 
Review Board. This study was carried out in compliance with the Helsinki Declaration. 
From the American College of Rheumatology (ACR) membership file, we selected all 
193 PRs and a random sample of 500 ARs with US addresses.  
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<<hd3>>Survey instrument and administration. We developed and refined 2 
parallel surveys, 1for ARs and 1 for PRs, to reflect the different nature of their practices 
in regards to pediatric patients. The survey focused on juvenile idiopathic arthritis (JIA), 
the most common rheumatologic condition in children. Specific survey items were drawn 
from the published literature on treatments for JIA and the pediatric rheumatology 
workforce, as well as the principal investigator’s clinical practice.  
Items included on both the pediatric and adult surveys were study eligibility (i.e., 
provision of care for children age <18 years with JIA), number of pediatric rheumatology 
patients seen in the outpatient and inpatient settings, practice patterns related to the 
treatment of various subtypes of JIA (explored via 4 case vignettes), resources utilized 
when making treatment decisions, practice setting, and year of residency completion. 
 Items included only on the adult survey were limitations in outpatient practice by 
patient age or diagnosis; attitudes related to comfort in diagnosing and treating JIA, 
factors influencing decisions to treat children, and adequacy of resources to treat children 
with JIA; information needs related to caring for children with JIA; patterns for referral 
of JIA patients to PRs; and extent of pediatric training during rheumatology fellowship. 
Items included only on the pediatric survey were attitudes related to appropriateness of 
JIA referrals and barriers to treatment and practice patterns and preferences related to co-
management of JIA patients with ARs. 
Survey questions encompassed a variety of formats, including Likert scales, 
fixed-choice response items, and open-response items; formats were tailored to question 
type and content. Questions were pilot tested with a convenience sample of physicians to 
assess clarity and ease of administration, and revisions were made based on pilot test 
feedback. The survey instruments are provided in Supplementary Appendix A (available 
on the Arthritis Care & Research web site 
at http://onlinelibrary.wiley.com/doi/10.1002/acr.23273/abstract).  
The survey mailings included a personalized cover letter inviting participation, 
and a postage-paid reply envelope. The initial mailing was sent in March 2009 and 
included a $2 cash incentive. After 5 weeks, a second mailing was sent to 
nonrespondents. 
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<<hd3>>Data analysis. Survey responses were coded, entered, and verified. 
Only those respondents who reported providing care to children ages 0–17 years with JIA 
were eligible for further analysis. For this group, we generated frequency distributions 
and conducted bivariate analysis using a likelihood chi-square test; P values less than 
0.05 were considered statistically significant. For items common to both surveys, 
bivariate analyses compared ARs and PRs. Analysis of the clinical vignettes included 
only those ARs who reported caring for children in the age range described in the 
vignette, as our intention was to report the treatment choices of those who actually 
provide care in the case described. Additional bivariate analyses were conducted for 
items specific to adult and to pediatric surveys. All analyses were conducted using SAS, 
version 9.1..  
 
<<hd1>>RESULTS 
 
Of the 693 surveys mailed, 444 were returned, while 9 were undeliverable, for a 64.9% 
response rate; the response rate was 62.1% for ARs (n = 306) and 72.3% for PRs (n = 
138). Only 23% of responding ARs (n = 69), but 93% of PRs (n = 128), reported that 
they provide direct patient care for children ages 0–17 years with JIA and were eligible 
for subsequent analyses.  
 
<<hd3>>Characteristics of eligible respondents. Table 1 presents 
characteristics of the 197 eligible respondents. <<T1>> With respect to practice setting, 
PRs were concentrated in academic medical centers, while more ARs practiced in private 
clinics. The majority of ARs (64%) limited their practice based on patient age; in 
addition, 4% limited their practice by diagnosis, excluding children with systemic lupus 
erythematosus/connective tissue disease. Of those who limit their practice by patient age, 
58% only treat children age >10 years (Table 1), with a very small minority seeing 
children age <6 years. Just under half of adult respondents (49%) were listed with a 
pediatric designation in the ACR membership directory. ARs practicing more than 50 
miles from a PR were more likely to not place age limits for their pediatric practice 
compared to those within 50 miles (68% versus 32%; P = 0.001). 
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<<hd3>>Attitudes of ARs about JIA care. Of ARs who reported caring for 
pediatric patients with JIA, 94% strongly agreed/agreed that they are comfortable 
diagnosing JIA in children. However, only 76% report being comfortable treating JIA, 
and 72% felt they were up to date on the latest advances in JIA treatment. While 75% felt 
there were adequate resources to assist them in treating JIA, only 51% agreed that 
medications to treat JIA have clear dosing guidelines. Over half (55%) agreed "lack of 
pediatric rheumatologists leads me to treat children with JIA myself."  
Table 2 presents the attitudes of ARs, stratified by the limits they place on their 
pediatric patient population. <<T2>> Consistently, ARs who limited their pediatric 
practice to older adolescents expressed the most hesitancy about JIA care. 
ARs reporting 0–1 outpatient pediatric visits per week were more likely than 
those with ≥2 pediatric visits per week to report being uncomfortable diagnosing JIA 
(11% versus 0%; P = 0.04) and treating JIA (39% versus 4%; P < 0.001), and were less 
likely to feel they were up to date on JIA treatments (42% versus 8%; P = 0.002). Those 
with training from a PR during fellowship were more likely to report adequate resources 
to assist them (91% versus 62%; P = 0.007), but otherwise they did not report more 
comfort diagnosing or treating JIA.  
 
<<hd3>>Impact of specialty on medication preference.  Four clinical vignettes 
were presented to survey respondents, representing a range of JIA subtypes. For each 
vignette, respondents selected the treatment(s) they would recommend as initial therapy, 
and whether the patient was refractory after 3 months of the initial treatment. The 
vignettes presented were 1) a 2-year-old with oligoarticular JIA, 2) a 6-year-old with 
systemic onset JIA, 3) a 9-year-old with polyarticular JIA without rheumatoid factor 
(RF), and 4) a 14-year-old with RF-positive polyarticular JIA. Full descriptions of the 
vignettes are located in Supplementary Appendix B (available on the Arthritis Care & 
Research web site at http://onlinelibrary.wiley.com/doi/10.1002/acr.23273/abstract).  
The clinical vignettes revealed several important prescribing differences (Table 
3). <<T3>> For the 2-year-old with oligoarticular JIA, ARs were more likely to initiate 
methotrexate treatment (12% versus 2%; P = 0.02); conversely, for the 9-year-old with 
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RF-negative polyarticular JIA, PRs were more likely to initiate methotrexate treatment 
(74% versus 44%; P = 0.0005) and to treat with a tumor necrosis factor (TNF) inhibitor 
(79% versus 54%; P = 0.003). PRs were more likely to treat the refractory 6-year-old 
with systemic JIA with anakinra (58% versus 38%; P = 0.04), and to initiate a TNF 
inhibitor for the 14-year-old with RF-positive polyarticular JIA (21% versus 7%; P < 
0.01).   
 
<<hd3>>Association of rheumatology training and practice setting on 
treatment selection. ARs with training from a PR differed in their prescribing patterns 
compared to those with pediatric training from ARs. Those with training from a PR were 
more likely to treat RF-positive JIA with steroid injections (25% versus 7%; P = 0.05) 
and were less likely to refer to a PR at the initial visit (0% versus 10%; P = 0.03). There 
was also a trend toward higher rates of initial methotrexate use by those with training 
from a PR (90% versus 72%; P = 0.06). The most significant results, however, were seen 
in the treatment of polyarticular JIA, where ARs with training from a PR were more 
likely to select methotrexate for initial treatment (44% versus 21%; P = 0.05) and TNF 
inhibitors for refractory disease (58% versus 32%; P = 0.04), and less likely to select oral 
steroids (0% versus 11%; P = 0.03). ARs practicing in academic centers were less likely 
to select TNF inhibitors (0% versus 19%) and initial intraarticular injections (0% versus 
20%; P = 0.02) for the treatment of oligoarticular JIA. The only significant difference 
among pediatric respondents based on training was in the selection of TNF inhibitors for 
polyarticular JIA, with those who trained after 1995 being more likely to select a TNF 
inhibitor than those who trained prior to 1995 (87% versus 71%; P = 0.03. 
 
<<hd3>>Information and education needs for JIA. While ARs report higher 
rates of disagreement with the statement "medications to treat JIA have clear dosing 
guidelines" at 48%, almost one-third of PRs also disagree with this statement (31%). ARs 
who felt there were not clear dosing guidelines were more likely to refer patients age <10 
years to a PR, with 86% often or always referring these children. 
The most common information and education needs of ARs were updates on 
diagnostic and therapeutic advances in JIA (63%) and pediatric dosing guidelines by 
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age/weight (53%). While over half of respondents felt dosing guidelines were needed, 
only 32% selected needing guidelines/algorithms to assist in choosing medications. Only 
7% of respondents indicated they had no informational or educational needs in caring for 
pediatric JIA patients. 
 
<<hd3>>Referral of pediatric JIA patients. The majority of ARs caring for 
pediatric JIA patients (n = 69) refer their patients to PRs in refractory cases and for 
children age <10 years (Figure 1). <<F1>> Conversely, ARs seemed comfortable with 
initiation of disease-modifying antirheumatic drugs, referring less often for that reason. 
PRs expressed a different view of referral. Of 115 PRs surveyed, almost half 
reported they did not feel ARs referred JIA patients to them at an appropriate time in the 
child's disease course. The vast majority of PRs report taking over all rheumatologic care 
for most or all patients referred from ARs. Co-management of the patient, or returning 
the patient back to the AR, is reported to be uncommon. 
 
<<hd3>>Co-management of patients. To enhance co-management, 74% of 
pediatric respondents endorsed shared medical records. Most pediatric respondents also 
cited reimbursement (63%) and treatment guidelines (53%) as ways to facilitate co-
management. Only 27% felt telemedicine would enhance co-management. Of the 18% 
who selected “other,” the most common response was that they did not co-manage 
patients and/or they did not feel ARs should care for pediatric patients.  
 
<<hd1>>DISCUSSION 
 
This national survey of ARs and PRs was conducted to provide insights into the 
characteristics and prescribing practices for juvenile arthritis by ARs and PRs, the 
resources utilized to make treatment decisions, and the interactions between adult and 
pediatric providers.  
Consistent with previous reports, we found that while most ARs report being 
comfortable diagnosing JIA, nearly one-quarter feel uncomfortable treating these 
children. Our survey indicates that only 23% of ARs provide care for pediatric patients 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
with JIA, and many of these limit their practice to older children (age >10 years). Not 
surprisingly, we found that ARs who reported feeling uncomfortable treating JIA were 
more likely to limit the age of children they see and to refer their JIA patients to PRs.  
We considered the limited geographic distribution of PRs as a likely contributor 
to the need for ARs caring for children (10). In our study, 55% of ARs treating children 
agreed that the lack of PRs leads them to treat children themselves, despite the majority 
of them practicing within 50 miles of a PR. While we consider distance to be an 
important factor that affects access to care, we do not have information from patients or 
their primary care providers regarding what is considered a reasonable distance to travel 
for subspecialty care. Furthermore, the contribution of other factors such as long weight 
times, insurance limitations, or family circumstances is unknown. Given the ongoing 
workforce limitations in pediatric rheumatology, further characterizing these limitations 
will be important to ultimately improve access to care.  
The clinical vignettes used in this survey study highlight important differences in 
treatment patterns, both initial and for refractory cases, between PRs and ARs. Treatment 
with intraarticular corticosteroids in oligoarticular disease among PRs was similar to a 
previous study (11,12); the lower utilization of intraarticular corticosteroids by ARs may 
reflect inexperience with injections in young children, or the lack of services for pediatric 
sedation. Compared to ARs, PRs were more likely to use methotrexate or biologic agents 
at the initial evaluation, and were more likely to select TNF inhibitors in the treatment of 
polyarticular JIA. This suggests that pediatric training may offer a different perspective 
on the treatment of JIA and the importance of early and aggressive therapy (13,14). 
Additionally, we found significant prescribing differences between ARs with and without 
training from a PR; this supports the importance of exposing adult rheumatology fellows 
to PRs during their training. From our results, it appears ARs are limiting the care they 
provide to mainly adolescents, and that after 3 months into treatment, they are treating 
children similarly. 
The lack of clear dosing guidelines for JIA treatments was endorsed by half of 
adult rheumatology respondents, but also by almost one-third of PRs. While review of the 
literature was reported as the most common mechanism for obtaining dosing regimens by 
both ARs and PRs, informal consultations with colleagues and information from national 
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meetings were also commonly used.  Further investigation into the nature of the 
information needed may help in developing resources to provide both PRs and ARs with 
easily accessible information. Simple dosing questions may be best presented in an 
electronic format. However, if the questions arising reflect more nuanced concerns or 
patient-specific issues, developing systems to improve access to a PR or experts may be 
more useful.  
ARs frequently refer pediatric patients to PRs for consultation, but it appears that 
few PRs participate in co-management with adult providers, and even fewer refer the 
child back to the adult provider for all ongoing care. The motivation for adult providers to 
refer to PRs was not clearly delineated in our study, and we cannot differentiate if the 
intention was for a consultation versus a transfer of care. However, the fact that over one-
third of ARs reported referring often or always to "verify diagnosis and guide therapy" 
suggests at least a portion of adult providers may be seeking input only to confirm 
optimal treatment, but not to transfer all care. It is less clear how interested PRs were in 
co-managing or consulting on children with JIA, as almost half felt internist 
rheumatologists did not refer JIA patients at an appropriate time in their disease course. 
Many PRs commented that they did not see a role of adult providers caring for children, 
which may reflect either their personal opinion, or those of families that specifically 
request a consulting PR to take over their child’s care. 
Given the current workforce limitations, it is not feasible for PRs to care for all 
children with rheumatologic disease. To increase access to care for pediatric patients, it is 
likely that several changes within health care will be necessary. One method may include 
optimizing care for children with JIA treated by adult providers through 1) encouraging 
co-management relationships, 2) dissemination of evidence-based guidelines for the 
diagnosis and treatment of pediatric rheumatic disease, and 3) increased emphasis on 
pediatric training during adult fellowship training. This is particularly advantageous, as a 
2002 survey suggested that, compared to PRs alone, an additional 40% of the pediatric 
population lives within 50 miles of an internist rheumatologist who treats children (10).  
Alternatively, there may be an increasing role for physician extenders working directly 
with PRs; a 2004 survey indicated that almost half of PRs use physician extenders (2). 
Although varying models exist, incorporating physician extenders may result in 
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increasing the number of patients who can be seen (and therefore reducing wait times). 
These providers may be particularly helpful in increasing access in urban areas where 
they can work directly with PRs in a clinical setting. However, rural areas or states that 
do not have a PR may also benefit from physician extenders who have dedicated pediatric 
musculoskeletal training and experience. In these areas, telemedicine and expanding 
outreach clinics could greatly improve access in both rural and urban settings. 
Additional efforts to improve the pediatric rheumatology workforce are reviewed 
elsewhere (2) and include recommendations to increase the supply of PRs, increased 
education and reliance on general pediatricians, and use of telemedicine. Telemedicine 
may improve access, particularly in underserved areas where general pediatricians and 
physician extenders can facilitate medication monitoring, routine followups of patients 
with JIA who are responding well to treatment, and early recognition of a new patient 
with suspected JIA. However, a local provider with experience performing a 
musculoskeletal examination is essential for this modality. In our survey, few 
respondents felt telemedicine would enhance co-management. However, with the 
expansion of electronic medical records (EMRs) and increased comfort with technology 
in the medical community, we would expect some of these attitudes to change, especially 
if issues around reimbursement are addressed.  
There are several potential limitations to our study. As our data were collected in 
2009, changes to the health care system may impact access to care, provider beliefs, and 
current practices. The use of EMRs may increase the ability to co-manage patients; 
however, there is significant heterogeneity in available EMR systems and many do not 
have the ability to share data. In addition, our survey suggests that provider beliefs were a 
significant barrier to co-management and are unlikely to be influenced by EMR 
availability. While insurance rates have improved with the passing of the Affordable Care 
Act (ACA), it is unclear what impact this has had on access to pediatric specialist care. 
There were far fewer children affected by the ACA, with the number of uninsured 
children decreasing by only 1 million, compared to 16 million non-elderly adults between 
2013 and 2016 (15) (despite children making up almost one-quarter of the population). In 
addition, compared to other specialties, a 2015 study found that rheumatology was more 
commonly excluded from insurance plans purchased through open enrollment in the 
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federal marketplace (16). The significance of our study remains relevant due to 1) the 
continued limitations in the pediatric workforce, and 2) limited change in the distribution 
of PRs nationally, both for clinical care demands and for educational exposure in 
academic centers. For example, there are still 8 states with no PRs and several with fewer 
than 2 (17).  Consistent with the results of our study, most PRs continue to be 
concentrated in academic centers in large populated cities, with most continuing to split 
their time between research and educational responsibilities (17). It is therefore unlikely 
that exposure to a PR has significantly changed.  
Our study has additional limitations. Data are self-reported practices and 
perceptions of physicians; practice patterns were not independently validated through 
medical records or other means. Second, while randomization typically serves to reduce 
sampling bias, the survey methodology is prone to self-selection bias and 
exclusion/nonresponse bias, especially for rheumatologists not listed in the ACR 
membership directory. It is possible that the ACR membership directory overrepresents 
certain practitioner demographics (such as academic clinicians). It is reassuring that other 
surveys that have combined the ACR membership directory and the American Medical 
Association Physician Masterfile found a similar proportion of adult and PRs in academic 
practice seen in our survey (18). Although a random sample was requested, responses 
were received only from ARs who completed residency in or before 1985; thus, results 
do not reflect ARs who completed residency training in the last 20 years. It is not clear if 
the age discrepancy between adult and pediatric respondents is solely from the random 
sample of physicians provided, or if older rheumatologists were more likely to complete 
the survey. Other provider surveys also demonstrated a low response rate for younger 
rheumatologists (18). Despite the limitations inherent with surveys, the response rate for 
this study is excellent and higher than other rheumatology physician surveys (18), which 
may minimize the impact of bias.  
Nearly a quarter of surveyed ARs care for children with JIA, with most limiting 
their practice to older children. Due to workforce limitations, finding ways to facilitate 
optimal care for children with JIA treated by adult providers, rather than absorbing them 
into the pediatric practice, may provide greater access and improve care.  In general, we 
found there was more discomfort in treating JIA than in diagnosing it, with a lack of clear 
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dosing guidelines for treatments being endorsed by half of adult rheumatology 
respondents, as well as almost a third of PRs. Since our initial survey, the ACR has 
worked to address these concerns by publishing guidelines for the treatment of JIA (19). 
Our data support the importance of continuing to develop treatment guidelines for 
children with rheumatic diseases, and future directives should also focus on the best ways 
to update and disseminate this information to adult providers who may be caring for 
children.  
Finally, our survey indicated significant prescribing differences between ARs 
with and without training from a PR. The prescribing differences highlight that pediatric-
specific education for ARs is critical to improve comfort in diagnosis and managing 
childhood rheumatic disease. Educational efforts may capitalize on a multifaceted 
approach that includes 1) expanded courses and workshops in pediatric rheumatology at 
national meetings, 2) continued development and dissemination of ACR guidelines for 
pediatric rheumatic diseases, and “toolkits” for diagnosis and management of JIA 
designed for ARs, and 3) implementation of standardized learning modules for providers 
and practicing clinicians. It is hoped that fostering these educational activities will 
improve access to care and interactions between adult and pediatric providers.  
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Figure 1.  Frequency of referral from adult to pediatric rheumatologist. Sample size 
varies in each category by number of respondents; total number of respondents = 69. 
DMARD = disease-modifying antirheumatic drug. 
 
Table 1. Characteristics of eligible respondents by specialty* 
 Adult 
rheumatologists 
(n = 69) 
Pediatric 
rheumatologists 
(n = 128) 
Practice setting, %   
   Academic center, general hospital 20 9 
   Academic center, children’s hospital 3 85 
   Community hospital 23 4 
   Private clinic 62 11 
   Other 12 2 
Pediatric outpatients seen/week, mean (range) 2 (0–12) 29 (3–145) 
Pediatric inpatients seen/month, mean (range) 2 (0–20) 11 (0–185) 
Age limitation on pediatric outpatients, %  NA 
   No limits 36  
   No patients <3 years 6  
   No patients <6 years 22  
   No patients <11 years 26  
   No patients <16 years 10  
Distance from pediatric rheumatologist, %  NA 
   ≤50 miles  60  
   >50 miles 40  
Pediatric experience in fellowship, %  NA 
   Adult rheumatologist preceptor 48  
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   Pediatric rheumatologist preceptor 52  
Year residency completed, mean (range) 1981 (1967–1985) 1993 (1967–2008) 
* Columns add to >100%, as some respondents have multiple practice settings. NA = not 
applicable. 
 
¶ 
Table 2. Adult rheumatologist attitudes on JIA care, by pediatric practice limits* 
 
Strongly disagree/ 
disagree, % 
Strongly agree/ 
agree, % P 
I am comfortable diagnosing JIA in children    
   No age limits 0 100 0.03 
   No patients age <3 years 0 100  
   No patients age <11 years 14 86  
I am comfortable treating children with JIA    
   No age limits 4 96 < 0.001 
   No patients age <3 years 7 93  
   No patients age <11 years 50 50  
I am up to date on the latest advances in JIA 
      treatment   
   
   No age limits 12 88 < 0.005 
   No patients age <3 years 14 86  
   No patients age <11 years 48 52  
Medications to treat JIA have clear dosing 
      guidelines 
   
   No age limits 40 60 0.34 
   No patients age <3 years 43 57  
   No patients age <11 years 59 41  
* JIA = juvenile idiopathic arthritis.  
 
 
Table 3: Treatment selection by JIA subtype based on clinical vignettes* 
 2-year-old: oJIA  6-year-old: soJIA  9-year-old: pJIA  14-year-old: RF+: pJIA  
 
Adult  
(n = 25) 
Ped. 
(n = 128)  
Adult 
(n = 33) 
Ped. 
(n = 128)  
Adult 
(n = 39) 
Ped. 
(n = 128)  
Adult 
(n = 59) 
Ped. 
(n = 127)  
NSAID 80 89  73 88†  90 95  79 93‡  
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MTX             
   Initial 12 2†  39 55  44 74‡  81 89  
   Refractory 32 52  38 27  46 24†  14 9  
   Total 44 54  77 82  90 98  95 98  
TNFi             
   Initial 0 0  3 1  0 5  7 21‡  
   Refractory 16 9  19 32  54‡ 79‡  77 74  
Oral steroids    64 69  23 25  38 42  
Steroid inj.              
   Initial 48 63     23 17  17 9  
   Refractory 28 28           
ANK             
   Initial    12 10        
   Refractory    38 56†        
ABT          0 0  
   Initial          3 12  
   Refractory             
             
* The sample size (n) for adult rheumatologist varies, as only those respondents who reported seeing children of each age were included 
in analyses. Sulfasalazine, hydroxychloroquine, and leflunomide were selected by fewer than 10% of respondents; results not shown. 
JIA = juvenile idiopathic arthritis; oJIA = oligoarticular JIA; soJIA = systemic onset JIA; pJIA = polyarticular JIA; RF = rheumatoid 
factor; NSAID = nonsteroidal antirheumatic drug; MTX = methotrexate; TNFi = tumor necrosis factor inhibitor; ANK = anakinra; ABT 
= abatacept. 
† P < 0.05. 
‡ P < 0.01. 
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